Related Experiment Videos
Human anti-self antibodies with high specificity from phage display libraries
A D Griffiths1, M Malmqvist, J D Marks
1MRC Centre for Protein Engineering, Cambridge, UK.
The EMBO Journal
|February 1, 1993
Summary
Researchers isolated human antibody fragments that bind to self-antigens from unimmunized donors. These antibody fragments, derived from peripheral blood lymphocytes (PBLs), show high specificity and can be engineered for therapeutic applications.
Area of Science:
- Immunology
- Molecular Biology
- Biotechnology
Background:
- Human antibody fragments binding foreign antigens can be isolated from peripheral blood lymphocytes (PBLs).
- V-genes from PBL mRNA can be shuffled and displayed as single-chain Fv (scFv) fragments on phage for antigen selection.
Purpose of the Study:
- To investigate the isolation of scFv fragments binding human self-antigens from a phage library.
- To characterize the binding kinetics and potential therapeutic applications of these self-antigen-binding scFv fragments.
Main Methods:
- Phage display library construction using shuffled heavy and light chain V-genes from unimmunized human PBLs.
- Selection of scFv fragments by phage binding to human self-antigens.
- Analysis of scFv fragment composition (monomers/dimers) using FPLC gel filtration.
- Determination of binding kinetics (association, dissociation, affinity) using surface plasmon resonance.
Main Results:
- Isolation of scFv fragments with high specificity for human self-antigens from the phage library.
- Identification of both unmutated and mutated V-genes encoding these self-reactive scFv fragments.
- Characterization of scFv dimer binding kinetics: association (k(on) = 10^5-10^6 M^-1s^-1), dissociation (k(off) = 10^-2 s^-1), and affinity (Ka = 10^7 M^-1).
- Observed relatively fast dissociation kinetics for the scFv dimers.
Conclusions:
- Phage libraries derived from human PBLs can yield scFv fragments with high specificity for self-antigens.
- The binding kinetics, particularly dissociation rates, suggest potential for in vitro affinity maturation for therapeutic purposes.
- Engineered antibody fragments could offer novel therapeutic strategies targeting self-antigens.